Hims & Hers Health Stock Is Rising Monday: What's Going On?
Hims & Hers Health Inc (NYSE:HIMS) shares are trading higher Monday. The company is set to join to the S&P SmallCap 600 this ...
2 Next-Gen Weight Loss Stocks That Are Worth Buying Right Now
While there's some ambiguity about the term "next generation" when it comes to weight loss therapies, one thing is clear: ...
Eli Lilly and Company (LLY): Hedge Funds Are Bullish On This Momentum Stock Now
We recently compiled a list of the 8 Best Momentum Stocks To Invest In Right Now. In this article, we are going to take a ...
Medscape6h
Tirzepatide Shortage Resolved? FDA Says Yes, Compounders No
Tirzepatide injection (Zepbound, Mounjaro) is officially off the FDA's drug shortage list, meaning compounders can no longer prepare and dispense the drug.
BioSpace10h
Can CB1 Inhibitors Make a Comeback in Obesity?
After psychological side effects doomed the first generation of cannabinoid receptor 1–targeting drugs for weight loss, Novo ...
Economist Justin Wolfers Points To Obesity Rate Decline As Ozempic And Wegovy Spur Historic Shift In Fight Against Obesity — Has US Reached A Turning Point?
The United States may have reached a turning point in its decades-long battle against obesity. Recent data suggests that 2020 ...
Regeneron co-founder warns of harms from weight-loss drugs: FT
The co-founder of biotech firm Regeneron Pharmaceuticals (REGN) said in a newspaper interview that popular weight-loss drugs ...